Covidien may sell drugs unit: source
PHILADELPHIA/BANGALORE (Reuters) - Covidien Plc (COV.N) is looking to sell its pharmaceuticals unit for as much as $4 billion, a source familiar with the situation said on Tuesday.
JPMorgan Chase & Co (JPM.N) is advising Covidien on the matter, said the source, who declined to be named because the information was not public.
Covidien may decide to keep the drugs unit if the auction fails to generate high-enough offers, the source said.
The maker of surgical products, drugs and medical supplies had been in talks with another healthcare company for the drugs business, but those talks failed, according to a report by Bloomberg.
Neither Covidien nor JPMorgan Chase was immediately available for comment.
In April, Covidien, based in Mansfield, Mass., reported a higher-than-expected second-quarter profit, helped by strong demand for its medical devices, and raised its full-year revenue growth forecast.
Shares of Covidien have gained 19.4 percent so far this year. The stock closed at $54.31, up $1.03, on the New York Stock exchange.
NEW YORK - U.S. stocks finished mostly higher on Friday, with the S&P 500 closing at a record after more jobs than expected were created in February and January's figure was revised higher. | Video
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.